Literature DB >> 34761259

Clinical characterization of a novel RAB39B nonstop mutation in a family with ASD and severe ID causing RAB39B downregulation and study of a Rab39b knock down mouse model.

Maria Lidia Mignogna1, Romina Ficarella2, Susanna Gelmini1, Lucia Marzulli3, Emanuela Ponzi2, Alessandra Gabellone3, Antonia Peschechera3, Massino Alessio4, Lucia Margari3, Mattia Gentile2, Patrizia D'Adamo1.   

Abstract

Autism spectrum disorder (ASD) and intellectual disability (ID) often exist together in patients. The RAB39B gene has been reported to be mutated in ID patients with additional clinical features ranging from ASD, macrocephaly, seizures and/or early-onset parkinsonism. Here, we describe a novel RAB39B nonstop mutation [Xq28; c.640 T > C; p.(*214Glnext*21)] in a family with ASD, severe ID and poor motor coordination, and we assessed the pathogenicity of the mutation. A heterologous cell system and a Rab39b knockdown (KD) murine model, which mimic the nonstop mutation, were used to validate the deleterious effect of the RAB39B mutation. The mutation led to RAB39B protein instability, resulting in its increased degradation and consequent downregulation. Using a Rab39b KD mouse model, we demonstrated that the downregulation of RAB39B led to increased GluA2 lacking Ca2+-permeable AMPAR composition at the hippocampal neuronal surface and increased dendritic spine density that remained in an immature filopodia-like state. These phenotypes affected behavioural performance in a disease-specific manner. Rab39b KD mice revealed impaired social behaviour but intact social recognition. They also showed normal anxiety-like, exploratory and motivational behaviours but impaired working and associative memories. In conclusion, we found a novel RAB39B nonstop variant that segregated in a family with a clinical phenotype including ID, ASD and poor motor coordination. The pathogenicity of mutations causing the downregulation of RAB39B proteins, impacting AMPAR trafficking and dendritic spine morphogenesis, reinforced the idea that AMPAR modulation and dendritic spine assets could be considered hallmarks of neurodevelopmental disorders.
© The Author(s) 2021. Published by Oxford University Press.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34761259      PMCID: PMC9071400          DOI: 10.1093/hmg/ddab320

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   5.121


  45 in total

1.  Broad clinical phenotype in Parkinsonism associated with a base pair deletion in RAB39B and additional POLG variant.

Authors:  Max Güldner; Claudia Schulte; Ann-Kathrin Hauser; Thomas Gasser; Kathrin Brockmann
Journal:  Parkinsonism Relat Disord       Date:  2016-07-15       Impact factor: 4.891

Review 2.  Gene hunting in autism spectrum disorder: on the path to precision medicine.

Authors:  Daniel H Geschwind; Matthew W State
Journal:  Lancet Neurol       Date:  2015-04-16       Impact factor: 44.182

Review 3.  RAB GTPases and RAB-interacting proteins and their role in the control of cognitive functions.

Authors:  Patrizia D'Adamo; Michela Masetti; Veronica Bianchi; Lorenzo Morè; Maria Lidia Mignogna; Maila Giannandrea; Silvia Gatti
Journal:  Neurosci Biobehav Rev       Date:  2014-01-09       Impact factor: 8.989

4.  Most genetic risk for autism resides with common variation.

Authors:  Trent Gaugler; Lambertus Klei; Stephan J Sanders; Corneliu A Bodea; Arthur P Goldberg; Ann B Lee; Milind Mahajan; Dina Manaa; Yudi Pawitan; Jennifer Reichert; Stephan Ripke; Sven Sandin; Pamela Sklar; Oscar Svantesson; Abraham Reichenberg; Christina M Hultman; Bernie Devlin; Kathryn Roeder; Joseph D Buxbaum
Journal:  Nat Genet       Date:  2014-07-20       Impact factor: 38.330

5.  The intellectual disability protein RAB39B selectively regulates GluA2 trafficking to determine synaptic AMPAR composition.

Authors:  Maria Lidia Mignogna; Maila Giannandrea; Antonia Gurgone; Francesca Fanelli; Francesco Raimondi; Lisa Mapelli; Silvia Bassani; Huaqiang Fang; Eelco Van Anken; Massimo Alessio; Maria Passafaro; Silvia Gatti; José A Esteban; Richard Huganir; Patrizia D'Adamo
Journal:  Nat Commun       Date:  2015-03-18       Impact factor: 14.919

6.  Forebrain deletion of αGDI in adult mice worsens the pre-synaptic deficit at cortico-lateral amygdala synaptic connections.

Authors:  Veronica Bianchi; Frédéric Gambino; Luca Muzio; Daniela Toniolo; Yann Humeau; Patrizia D'Adamo
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

7.  Intellectual development in autism spectrum disorders: new insights from longitudinal studies.

Authors:  Giacomo Vivanti; Josephine Barbaro; Kristelle Hudry; Cheryl Dissanayake; Margot Prior
Journal:  Front Hum Neurosci       Date:  2013-07-05       Impact factor: 3.169

8.  Mutations in RAB39B in individuals with intellectual disability, autism spectrum disorder, and macrocephaly.

Authors:  Marc Woodbury-Smith; Eric Deneault; Ryan K C Yuen; Susan Walker; Mehdi Zarrei; Giovanna Pellecchia; Jennifer L Howe; Ny Hoang; Mohammed Uddin; Christian R Marshall; Christina Chrysler; Ann Thompson; Peter Szatmari; Stephen W Scherer
Journal:  Mol Autism       Date:  2017-11-09       Impact factor: 7.509

9.  RAB39B-mediated trafficking of the GluA2-AMPAR subunit controls dendritic spine maturation and intellectual disability-related behaviour.

Authors:  Maria Lidia Mignogna; Stefano Musardo; Giulia Ranieri; Susanna Gelmini; Pedro Espinosa; Paolo Marra; Sara Belloli; Valentina Murtaj; Rosa Maria Moresco; Camilla Bellone; Patrizia D'Adamo
Journal:  Mol Psychiatry       Date:  2021-05-25       Impact factor: 15.992

10.  Deletion of the mental retardation gene Gdi1 impairs associative memory and alters social behavior in mice.

Authors:  Patrizia D'Adamo; Hans Welzl; Stavros Papadimitriou; Marina Raffaele di Barletta; Cecilia Tiveron; Laura Tatangelo; Laura Pozzi; Paul F Chapman; Simon G Knevett; Mark F Ramsay; Flavia Valtorta; Chiara Leoni; Andrea Menegon; David P Wolfer; Hans-Peter Lipp; Daniela Toniolo
Journal:  Hum Mol Genet       Date:  2002-10-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.